Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-14 Mln
ROE
-4.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.8
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
-0.3
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
5,962,560
CFO
$-226.62 Mln
EBITDA
$-273.29 Mln
Net Profit
$-279.76 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
OncoSec Medical Inc (ONCS)
| -100.0 | -99.7 | -100.0 | -100.0 | -98.7 | -94.2 | -79.2 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
OncoSec Medical Inc (ONCS)
| -92.0 | -85.1 | 256.4 | -71.7 | -60.4 | 32.1 | -48.1 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
OncoSec Medical Inc (ONCS)
|
0.0 | 1.7 | 0.0 | -30.1 | -- | -- | -- | 0.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's... product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. Read more
Pres, CEO & Non-Independent Director
Dr. Robert H. Arch Ph.D.
Pres, CEO & Non-Independent Director
Dr. Robert H. Arch Ph.D.
Headquarters
Pennington, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of OncoSec Medical Inc (ONCS) is $0.00 (NASDAQ) as of 25-Aug-2023 09:30 EDT. OncoSec Medical Inc (ONCS) has given a return of -98.66% in the last 3 years.
Since, TTM earnings of OncoSec Medical Inc (ONCS) is negative, P/E ratio is not available.
The P/B ratio of OncoSec Medical Inc (ONCS) is 0.78 times as on 25-Aug-2023, a 80 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of OncoSec Medical Inc (ONCS) are Rs -- and Rs -- as of 04-Apr-2026.
OncoSec Medical Inc (ONCS) has a market capitalisation of $ 2 Mln as on 25-Aug-2023. As per SEBI classification, it is a company.
Before investing in OncoSec Medical Inc (ONCS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.